ADVATE has health-related quality-of-life results1
ADVATE has shown clinically meaningful improvements in physical functioning, well-being, general health, and/or energy level, based on physical component score.†1-3
Reduced levels of pain and improvements in the limitations of work due to pain.1,2
Improvements in the ability to perform work or other daily activities.1,2
Changes not observed in limitations to a range of minor and major physical activities.1,2
Changes not observed in the views and expectations of overall health.1,2
†Clinically meaningful changes were not seen in the mental health-related component score and subcategories of Mental Health, Role Emotional, Social Functioning, and Vitality.
Prophylaxis with ADVATE improved physical health-related quality of life compared with on-demand treatment1
After 12 months of prophylactic treatment, physical health-related quality of life improved in patients, mainly due to clinically meaningful improvements in1-3:
The amount of pain experienced by a patient and how much pain interferes with normal work.
The impact physical health can have on performing work or other daily activities.
Clinically meaningful changes were not seen in1:
The physical health-related subcategories of General Health and Physical Functioning.
The mental health-related component score and subcategories of Mental Health, Role Emotional, Social Functioning, and Vitality.
Selected Important Risk Information
Warnings & Precautions
Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.
Please see additional detailed important risk information below.
Advate. Prescribing information. Baxalta US Inc; 2018.
Maruish ME, ed. User’s Manual for the SF-36v2 Health Survey. 3rd ed. QualityMetric Incorporated; 2011.
Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367. Published correction appears in J Thromb Haemost. 2012;10(6):1204.
You are now leaving ADVATEPro.com
Takeda does not review, endorse, or control the content of any non-Takeda site. Takeda is not responsible for the accuracy, content, practices, or standards of any non-Takeda resources accessed through a link on this site.